1. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
by Rishi K. Wadhera, Robert A. Kyle, Dirk R. Larson, Angela Dispenzieri, Shaji Kumar, Hillard M. Lazarus, and S. Vincent Rajkumar
Blood
Volume 118(11):
September 15, 2011
©2011 by American Society of Hematology

2. OS among all patients.
OS among all patients. Median overall survival was 73 months in patients with secondary MGUS versus 38 months in the rest of the cohort (P < .001). Cum. survival indicates cumulative survival.
Rishi K. Wadhera et al. Blood 2011;118:
©2011 by American Society of Hematology